{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:08:35Z","timestamp":1791925715510,"version":"4.3.4"},"reference-count":87,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":2162,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P01AG030128"],"award-info":[{"award-number":["P01AG030128"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1074\/jbc.m114.600833","type":"journal-article","created":{"date-parts":[[2014,9,13]],"date-time":"2014-09-13T06:57:33Z","timestamp":1410591453000},"page":"30538-30555","source":"Crossref","is-referenced-by-count":89,"title":["Amyloid-\u03b2 Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in Vivo"],"prefix":"10.1016","volume":"289","author":[{"given":"Leon M.","family":"Tai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Ben Aissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.J.","family":"Thatcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jo","family":"LaDu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1074\/jbc.M114.600833_bib1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jalz.2013.02.003","article-title":"2013 Alzheimer's disease facts and figures","volume":"9","author":"Thies","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1074\/jbc.M114.600833_bib2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","article-title":"Soluble amyloid \u03b2 peptide concentration as a predictor of synaptic change in Alzheimer's disease","volume":"155","author":"Lue","year":"1999","journal-title":"Am. J. Pathol"},{"key":"10.1074\/jbc.M114.600833_bib3","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","article-title":"Soluble pool of A\u03b2 amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease","volume":"46","author":"McLean","year":"1999","journal-title":"Ann. Neurol"},{"key":"10.1074\/jbc.M114.600833_bib4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1006\/exnr.1999.7085","article-title":"The levels of soluble versus insoluble brain A\u03b2 distinguish Alzheimer's disease from normal and pathologic aging","volume":"158","author":"Wang","year":"1999","journal-title":"Exp. Neurol"},{"key":"10.1074\/jbc.M114.600833_bib5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2009.05.024","article-title":"Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction","volume":"35","author":"Tomic","year":"2009","journal-title":"Neurobiol. Dis"},{"key":"10.1074\/jbc.M114.600833_bib6","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1073\/pnas.1017033108","article-title":"Soluble amyloid \u03b2-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration","volume":"108","author":"Jin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.M114.600833_bib7","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1074\/jbc.271.8.4077","article-title":"Water-soluble A\u03b2 (N-40, N-42) oligomers in normal and Alzheimer disease brains","volume":"271","author":"Kuo","year":"1996","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M114.600833_bib8","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/nm.2460","article-title":"Resolving controversies on the path to Alzheimer's therapeutics","volume":"17","author":"Selkoe","year":"2011","journal-title":"Nat. Med"},{"key":"10.1074\/jbc.M114.600833_bib9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJMe1313943","article-title":"Antiamyloid therapy for Alzheimer's disease\u2013are we on the right road?","volume":"370","author":"Karran","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.M114.600833_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/jcpt.12112","article-title":"Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches","volume":"39","author":"Mikulca","year":"2014","journal-title":"J. Clin. Pharm. Ther"},{"key":"10.1074\/jbc.M114.600833_bib11","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1126\/science.1217697","article-title":"ApoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models","volume":"335","author":"Cramer","year":"2012","journal-title":"Science"},{"key":"10.1074\/jbc.M114.600833_bib12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1326-8-18","article-title":"Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP\/PS1 mice","volume":"8","author":"LaClair","year":"2013","journal-title":"Mol. Neurodegener"},{"key":"10.1074\/jbc.M114.600833_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/science.1235809","article-title":"Comment on apoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models","volume":"340","author":"Fitz","year":"2013","journal-title":"Science"},{"key":"10.1074\/jbc.M114.600833_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/science.1234089","article-title":"Comment on apoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models","volume":"340","author":"Price","year":"2013","journal-title":"Science"},{"key":"10.1074\/jbc.M114.600833_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233937","article-title":"Comment on apoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models","volume":"340","author":"Tesseur","year":"2013","journal-title":"Science"},{"key":"10.1074\/jbc.M114.600833_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/science.1235505","article-title":"Comment on apoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models","volume":"340","author":"Veeraraghavalu","year":"2013","journal-title":"Science"},{"key":"10.1074\/jbc.M114.600833_bib17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.bbalip.2010.05.001","article-title":"Proposed mechanism for lipoprotein remodelling in the brain","volume":"1801","author":"Yu","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1074\/jbc.M114.600833_bib18","doi-asserted-by":"crossref","first-page":"41197","DOI":"10.1074\/jbc.M407962200","article-title":"Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain","volume":"279","author":"Hirsch-Reinshagen","year":"2004","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M114.600833_bib19","doi-asserted-by":"crossref","first-page":"40987","DOI":"10.1074\/jbc.M407963200","article-title":"ABCA1 is required for normal central nervous system apoE levels and for lipidation of astrocyte-secreted apoE","volume":"279","author":"Wahrle","year":"2004","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M114.600833_bib20","doi-asserted-by":"crossref","first-page":"43243","DOI":"10.1074\/jbc.M508781200","article-title":"The absence of ABCA1 decreases soluble apoE levels but does not diminish amyloid deposition in two murine models of Alzheimer's disease","volume":"280","author":"Hirsch-Reinshagen","year":"2005","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M114.600833_bib21","doi-asserted-by":"crossref","first-page":"43224","DOI":"10.1074\/jbc.M504513200","article-title":"Lack of ABCA1 considerably decreases brain apoE level and increases amyloid deposition in APP23 mice","volume":"280","author":"Koldamova","year":"2005","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M114.600833_bib22","doi-asserted-by":"crossref","first-page":"43236","DOI":"10.1074\/jbc.M508780200","article-title":"Deletion of Abca1 increases A\u03b2 deposition in the PDAPP transgenic mouse model of Alzheimer disease","volume":"280","author":"Wahrle","year":"2005","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M114.600833_bib23","doi-asserted-by":"crossref","first-page":"10601","DOI":"10.1073\/pnas.0701096104","article-title":"Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors","volume":"104","author":"Zelcer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.M114.600833_bib24","first-page":"671","article-title":"Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease","volume":"118","author":"Wahrle","year":"2008","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.M114.600833_bib25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3233\/JAD-2010-1255","article-title":"Use of genetic variation as biomarkers for mild cognitive impairment and progression of mild cognitive impairment to dementia","volume":"19","author":"Reitz","year":"2010","journal-title":"J. Alzheimers Dis"},{"key":"10.1074\/jbc.M114.600833_bib26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1515\/CCLM.2011.088","article-title":"The effect of apolipoprotein E (apoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease","volume":"49","author":"Leoni","year":"2011","journal-title":"Clin. Chem. Lab. Med"},{"key":"10.1074\/jbc.M114.600833_bib27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3233\/JAD-130716","article-title":"Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of apolipoprotein E4 allele","volume":"37","author":"Qiu","year":"2013","journal-title":"J. Alzheimers Dis"},{"key":"10.1074\/jbc.M114.600833_bib28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1074\/jbc.M114.600833_bib29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1212\/WNL.50.3.669","article-title":"Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease","volume":"50","author":"Farlow","year":"1998","journal-title":"Neurology"},{"key":"10.1074\/jbc.M114.600833_bib30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","article-title":"Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease","volume":"6","author":"Risner","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.1074\/jbc.M114.600833_bib31","doi-asserted-by":"crossref","first-page":"41774","DOI":"10.1074\/jbc.M112.407957","article-title":"APOE4-specific changes in A\u03b2 accumulation in a new transgenic mouse model of Alzheimer disease","volume":"287","author":"Youmans","year":"2012","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M114.600833_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(10)70325-2","article-title":"Apolipoprotein E in Alzheimer's disease and other neurological disorders","volume":"10","author":"Verghese","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1074\/jbc.M114.600833_bib33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1750-1326-9-2","article-title":"Soluble apoE\/A\u03b2 complex: mechanism and therapeutic target for APOE4-induced AD risk","volume":"9","author":"Tai","year":"2014","journal-title":"Mol. Neurodegener"},{"key":"10.1074\/jbc.M114.600833_bib34","doi-asserted-by":"crossref","first-page":"810981","DOI":"10.4061\/2011\/810981","article-title":"Introducing human APOE into A\u03b2 transgenic mouse models","volume":"2011","author":"Tai","year":"2011","journal-title":"Int. J. Alzheimers Dis"},{"key":"10.1074\/jbc.M114.600833_bib35","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1523\/JNEUROSCI.5198-13.2014","article-title":"Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene","volume":"34","author":"Boehm-Cagan","year":"2014","journal-title":"J. Neurosci"},{"key":"10.1074\/jbc.M114.600833_bib36","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1089\/thy.2013.0241","article-title":"Thyroid dysfunction as an unintended side effect of anticancer drugs","volume":"23","author":"Torino","year":"2013","journal-title":"Thyroid"},{"key":"10.1074\/jbc.M114.600833_bib37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3816\/CLM.2003.n.006","article-title":"Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma","volume":"3","author":"Sherman","year":"2003","journal-title":"Clin. Lymphoma"},{"key":"10.1074\/jbc.M114.600833_bib38","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1210\/endo.143.8.8930","article-title":"Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat","volume":"143","author":"Liu","year":"2002","journal-title":"Endocrinology"},{"key":"10.1074\/jbc.M114.600833_bib39","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1210\/en.2008-1540","article-title":"Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein","volume":"150","author":"de Vries-van der Weij","year":"2009","journal-title":"Endocrinology"},{"key":"10.1074\/jbc.M114.600833_bib40","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1021\/jm00016a018","article-title":"Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells","volume":"38","author":"Boehm","year":"1995","journal-title":"J. Med. Chem"},{"key":"10.1074\/jbc.M114.600833_bib41","doi-asserted-by":"crossref","first-page":"8432","DOI":"10.1021\/jm4008517","volume":"56","author":"Jurutka","year":"2013","journal-title":"J. Med. Chem"},{"key":"10.1074\/jbc.M114.600833_bib42","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1158\/1535-7163.MCT-05-0322","article-title":"Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide","volume":"5","author":"Wang","year":"2006","journal-title":"Mol. Cancer Ther"},{"key":"10.1074\/jbc.M114.600833_bib43","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ecl.2013.09.006","article-title":"Relationships between diabetes and cognitive impairment","volume":"43","author":"de la Monte","year":"2014","journal-title":"Endocrinol. Metab. Clin. North Am"},{"key":"10.1074\/jbc.M114.600833_bib44","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1097\/01.aids.0000192076.03443.6d","article-title":"Neurological and neuropsychiatric syndromes associated with liver disease","volume":"19","author":"Weissenborn","year":"2005","journal-title":"AIDS"},{"key":"10.1074\/jbc.M114.600833_bib45","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/qjmed\/hcg110","article-title":"The neurology of liver failure","volume":"96","author":"Lewis","year":"2003","journal-title":"QJM"},{"key":"10.1074\/jbc.M114.600833_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2110-5820-3-15","article-title":"Understanding brain dysfunction in sepsis","volume":"3","author":"Sonneville","year":"2013","journal-title":"Ann. Inten. Care"},{"key":"10.1074\/jbc.M114.600833_bib47","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1021\/jo0103064","article-title":"Synthesis of novel retinoid X receptor-selective retinoids","volume":"66","author":"Faul","year":"2001","journal-title":"J. Org. Chem"},{"key":"10.1074\/jbc.M114.600833_bib48","doi-asserted-by":"crossref","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","article-title":"Intraneuronal \u03b2-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation","volume":"26","author":"Oakley","year":"2006","journal-title":"J. Neurosci"},{"key":"10.1074\/jbc.M114.600833_bib49","doi-asserted-by":"crossref","first-page":"17972","DOI":"10.1074\/jbc.272.29.17972","article-title":"Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis","volume":"272","author":"Sullivan","year":"1997","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M114.600833_bib50","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1523\/JNEUROSCI.5170-04.2005","article-title":"Human apolipoprotein E4 alters the amyloid-\u03b2 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model","volume":"25","author":"Fryer","year":"2005","journal-title":"J. Neurosci"},{"key":"10.1074\/jbc.M114.600833_bib51","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1523\/JNEUROSCI.0887-09.2009","article-title":"Human APOE isoform-dependent effects on brain \u03b2-amyloid levels in PDAPP transgenic mice","volume":"29","author":"Bales","year":"2009","journal-title":"J. Neurosci"},{"key":"10.1074\/jbc.M114.600833_bib52","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1074\/jbc.M112.442103","article-title":"Levels of soluble apolipoprotein E\/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples","volume":"288","author":"Tai","year":"2013","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M114.600833_bib53","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jneumeth.2010.12.009","article-title":"A novel approach for long term oral drug administration in animal research","volume":"195","author":"Overk","year":"2011","journal-title":"J. Neurosci. Methods"},{"key":"10.1074\/jbc.M114.600833_bib54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1593\/neo.111440","article-title":"Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min\/+) mice","volume":"14","author":"Janakiram","year":"2012","journal-title":"Neoplasia"},{"key":"10.1074\/jbc.M114.600833_bib55","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.nbd.2011.08.035","article-title":"Effects of aromatase inhibition versus gonadectomy on hippocampal complex amyloid pathology in triple transgenic mice","volume":"45","author":"Overk","year":"2012","journal-title":"Neurobiol. Dis"},{"key":"10.1074\/jbc.M114.600833_bib56","first-page":"990","article-title":"Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors","volume":"29","author":"Howell","year":"2001","journal-title":"Drug Metab. Dispos"},{"key":"10.1074\/jbc.M114.600833_bib57","first-page":"467","article-title":"Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069","volume":"11","author":"Wu","year":"2002","journal-title":"Cancer Epidemiol. Biomarkers Prev"},{"key":"10.1074\/jbc.M114.600833_bib58","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jneumeth.2010.12.025","article-title":"Amyloid-\u03b242 alters apolipoprotein E solubility in brains of mice with five familial AD mutations","volume":"196","author":"Youmans","year":"2011","journal-title":"J. Neurosci. Methods"},{"key":"10.1074\/jbc.M114.600833_bib59","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jnr.22227","volume":"88","author":"Sultana","year":"2010","journal-title":"J. Neurosci. Res"},{"key":"10.1074\/jbc.M114.600833_bib60","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1073\/pnas.0811698106","article-title":"Oligomeric amyloid \u03b2 associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques","volume":"106","author":"Koffie","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.M114.600833_bib61","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.nbd.2005.02.008","article-title":"\u03b2-Amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses","volume":"20","author":"Almeida","year":"2005","journal-title":"Neurobiol. Dis"},{"key":"10.1074\/jbc.M114.600833_bib62","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s11481-014-9543-3","article-title":"Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38\u03b1 MAPK inhibitors","volume":"9","author":"Bachstetter","year":"2014","journal-title":"J. Neuroimmune Pharmacol"},{"key":"10.1074\/jbc.M114.600833_bib63","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","article-title":"ApoE promotes the proteolytic degradation of A\u03b2","volume":"58","author":"Jiang","year":"2008","journal-title":"Neuron"},{"key":"10.1074\/jbc.M114.600833_bib64","doi-asserted-by":"crossref","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","article-title":"Human apoE isoforms differentially regulate brain amyloid-\u03b2 peptide clearance","volume":"3","author":"Castellano","year":"2011","journal-title":"Sci. Transl. Med"},{"key":"10.1074\/jbc.M114.600833_bib65","doi-asserted-by":"crossref","first-page":"44593","DOI":"10.1074\/jbc.M112.420224","article-title":"Differential regulation of amyloid-\u03b2 endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms","volume":"287","author":"Li","year":"2012","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M114.600833_bib66","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1172\/JCI36663","article-title":"ApoE isoform-specific disruption of amyloid \u03b2 peptide clearance from mouse brain","volume":"118","author":"Deane","year":"2008","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.M114.600833_bib67","doi-asserted-by":"crossref","first-page":"E1807","DOI":"10.1073\/pnas.1220484110","article-title":"ApoE influences amyloid-\u03b2 (A\u03b2) clearance despite minimal apoE\/A\u03b2 association in physiological conditions","volume":"110","author":"Verghese","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.M114.600833_bib68","doi-asserted-by":"crossref","first-page":"11628","DOI":"10.1074\/jbc.M112.411900","article-title":"Binding of apolipoprotein E inhibits the oligomer growth of amyloid-\u03b2 peptide in solution as determined by fluorescence cross-correlation spectroscopy","volume":"288","author":"Ly","year":"2013","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M114.600833_bib69","doi-asserted-by":"crossref","first-page":"15181","DOI":"10.1523\/JNEUROSCI.1542-12.2012","article-title":"Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid \u03b2 peptide","volume":"32","author":"Hashimoto","year":"2012","journal-title":"J. Neurosci"},{"key":"10.1074\/jbc.M114.600833_bib70","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1471-4159.2011.07478.x","article-title":"Soluble A\u03b2 oligomer production and toxicity","volume":"120","author":"Larson","year":"2012","journal-title":"J. Neurochem"},{"key":"10.1074\/jbc.M114.600833_bib71","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1523\/JNEUROSCI.0572-14.2014","article-title":"Genetic modulation of soluble A\u03b2 rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease","volume":"34","author":"Fowler","year":"2014","journal-title":"J. Neurosci"},{"key":"10.1074\/jbc.M114.600833_bib72","doi-asserted-by":"crossref","first-page":"15861","DOI":"10.1523\/JNEUROSCI.3272-11.2011","article-title":"Dynamic analysis of amyloid \u03b2-protein in behaving mice reveals opposing changes in ISF versus parenchymal A\u03b2 during age-related plaque formation","volume":"31","author":"Hong","year":"2011","journal-title":"J. Neurosci"},{"key":"10.1074\/jbc.M114.600833_bib73","doi-asserted-by":"crossref","first-page":"212ra161","DOI":"10.1126\/scitranslmed.3007000","article-title":"Gene transfer of human apoE isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain","volume":"5","author":"Hudry","year":"2013","journal-title":"Sci. Transl. Med"},{"key":"10.1074\/jbc.M114.600833_bib74","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1042\/BJ20060914","article-title":"SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR","volume":"400","author":"Wong","year":"2006","journal-title":"Biochem. J"},{"key":"10.1074\/jbc.M114.600833_bib75","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1523\/JNEUROSCI.0630-12.2012","article-title":"\u03b2-Amyloid inhibits protein prenylation and induces cholesterol sequestration by impairing SREBP-2 cleavage","volume":"32","author":"Mohamed","year":"2012","journal-title":"J. Neurosci"},{"key":"10.1074\/jbc.M114.600833_bib76","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jgg.2014.04.003","article-title":"The involvement of lipids in Alzheimer's disease","volume":"41","author":"Lim","year":"2014","journal-title":"J. Genet. Genomics"},{"key":"10.1074\/jbc.M114.600833_bib77","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ana.24135","article-title":"Sex modifies the APOE-related risk of developing Alzheimer disease","volume":"75","author":"Altmann","year":"2014","journal-title":"Ann. Neurol"},{"key":"10.1074\/jbc.M114.600833_bib78","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/00002093-199910000-00007","article-title":"Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease","volume":"13","author":"Bretsky","year":"1999","journal-title":"Alzheimer Dis. Assoc. Disord"},{"key":"10.1074\/jbc.M114.600833_bib79","first-page":"803","article-title":"Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women","volume":"58","author":"Payami","year":"1996","journal-title":"Am. J. Hum. Genet"},{"key":"10.1074\/jbc.M114.600833_bib80","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/WNL.54.10.1949","article-title":"Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction","volume":"54","author":"Yaffe","year":"2000","journal-title":"Neurology"},{"key":"10.1074\/jbc.M114.600833_bib81","doi-asserted-by":"crossref","first-page":"e54713","DOI":"10.1371\/journal.pone.0054713","article-title":"Accelerated cell aging in female APOE-\u03f54 carriers: implications for hormone therapy use","volume":"8","author":"Jacobs","year":"2013","journal-title":"PLoS One"},{"key":"10.1074\/jbc.M114.600833_bib82","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neulet.2013.12.032","article-title":"APOE modulates the effect of estrogen therapy on A\u03b2 accumulation EFAD-Tg mice","volume":"560","author":"Kunzler","year":"2014","journal-title":"Neurosci. Lett"},{"key":"10.1074\/jbc.M114.600833_bib83","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bbalip.2011.04.003","article-title":"Modulation of RXR function through ligand design","volume":"1821","author":"P\u00e9rez","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1074\/jbc.M114.600833_bib84","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bjd.12042","article-title":"U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma","volume":"168","author":"Scarisbrick","year":"2013","journal-title":"Br. J. Dermatol"},{"key":"10.1074\/jbc.M114.600833_bib85","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2340\/00015555-1359","article-title":"Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland","volume":"92","author":"V\u00e4kev\u00e4","year":"2012","journal-title":"Acta Derm. Venereol"},{"key":"10.1074\/jbc.M114.600833_bib86","doi-asserted-by":"crossref","first-page":"946265","DOI":"10.1155\/2014\/946265","article-title":"Detection of impaired cognitive function in rat with hepatosteatosis model and improving effect of GLP-1 analogues (exenatide) on cognitive function in hepatosteatosis","volume":"2014","author":"Erbas","year":"2014","journal-title":"Scientific World J"},{"key":"10.1074\/jbc.M114.600833_bib87","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s10620-013-2657-2","article-title":"Functional impairment in alcoholic liver disease and nonalcoholic fatty liver disease is significant and persists over 3 years of follow-up","volume":"58","author":"Elliott","year":"2013","journal-title":"Digest. Dis. Sci"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820372604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820372604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1074\/jbc.M114.600833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T16:24:28Z","timestamp":1746375868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925820372604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":87,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0021925820372604"],"URL":"https:\/\/doi.org\/10.1074\/jbc.m114.600833","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}